Your healthcare provider may adjust your tirzepatide dosing for weight loss in units if side effects become intolerable
GLP-1 modulates appetite through two primary mechanisms: First, it upregulates key gastrointestinal hormones like CCK, gastrin, and GIP, which support digestion and send satiety signals to the brain
GLP-1-based drugs, such as semaglutide and tirzepatide, have transformed obesity treatment
doi: 10.3389/fimmu.2025.1610368 Received 11 April 2025 Accepted 26 June 2025 Published 15 July 2025 Volume 16 - 2025 Edited by Li-Tung Huang, Kaohsiung Chang Gung Memorial Hospital, Taiwan Reviewed by Beata Kasztelan-Szczerbinska, Medical University of Lublin, Poland Edit Posta, University of Debrecen, Hungary Updates Copyright 2025 Migliorisi, Gabbiadini, Dal Buono, Ferraris, Privitera, Petronio, Bertoli, Bezzio and Armuzzi
Reduced appetite while therapeutically intended, this can occasionally lead to inadequate nutritional intake Injection site reactions mild redness, bruising, or discomfort at the site of subcutaneous injection Fatigue and dizziness reported in a subset of trial participants, often associated with early treatment phases Hypoglycaemia (low blood sugar) uncommon with retatrutide alone, but the risk increases when it is used alongside insulin or sulfonylureas